New Copaxone Formulation Approved

From NeurologyWire

FDA has approved Tevas supplemental new drug application (sNDA) for three-times-a-week Copaxone 40mg/mL. This new formulation will allow for a less frequent dosing regimen administered subcutaneously for patients with relapsing forms of multiple sclerosis (MS). In addition to the newly approved dose, daily Copaxone 20 mg/mL will continue to be ava...

Login to read story

Thursday, April 24, 2014

Show last days of articles

Catalyst Initiates Program for Lambert-Eaton Myasthenic Synd...

From NeurologyWire

Catalyst Pharmaceutical Partners, Inc. has begun the process required to establish an expanded access program (EAP) to make available in the United St...Full story

Wednesday, April 23, 2014

Data Update on ADS-5102 (amantadine HCl) to Be Released

From NeurologyWire

Adamas Pharmaceuticals, Inc. announced a poster presentation at the American Academy of Neurology (AAN) 66th Annual Meeting, April 26 to May 3, 2014, ...Full story

Gene Sequencing Streamlines Epilepsy Diagnosis

From NeurologyWire

Quest Diagnostics announced a suite of new testing services from its Athena Diagnostics specialty neurology business designed to help physicians more ...Full story

Tuesday, April 22, 2014

Friday, April 18, 2014

Acorda Launches Seizure Site

From NeurologyWire

Acorda has launched "a website dedicated to providing information to healthcare professionals in an effort to help them serve som...Full story

Wednesday, April 16, 2014

Neuralstem Spinal Cord Injury Stem Cell Trial Approved To Co...

From NeurologyWire

Neuralstem, Inc. announced that the Institutional Review Board of the University of California, San Diego, School of Medicine has approved the Phase I...Full story

Free Brain Health Fair Coming to Philadelphia April 26

From NeurologyWire

World-class neurologists are coming to Philadelphia to host a free Brain Health Fair for all area residents and their families on Saturday, April 26, ...Full story

Tuesday, April 08, 2014

Four Paraplegic Men Voluntarily Move Their Legs, an "Unprece...

From NeurologyWire

Four young men who have been paralyzed for years achieved groundbreaking progress moving their legs as a result of epidural electrical stimulation o...Full story

Experts Available and Additional Antipsychotic Market Detail...

From NeurologyWire

Alkermes announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in pat...Full story

Monday, April 07, 2014

Genzyme to Resubmit Lemtrada Application for FDA Review

From NeurologyWire

Following discussions with FDA, Genzyme plans to resubmit in the second quarter its supplemental Biologics License Application (sBLA) seeking approval...Full story

Tuesday, April 01, 2014

Study Shows Neuralstem Cells Transplanted Into Brain Signifi...

From NeurologyWire

A study published in PLOS ONE showed that ischemic-stroke rats transplanted with Neuralstem's NSI-566 stem cells in the brain experienced functional i...Full story

Friday, March 28, 2014

Parkinson's Disease Foundation Announces $20,000 in Grant Fu...

From NeurologyWire

The Parkinson's Disease Foundation (PDF) is pleased to announce $20,000 in grant funding to support patient-centered research at four leading Parkinso...Full story

Thursday, March 13, 2014

Brain Injury Association of America Applauds Introduction of...

From NeurologyWire

During a press conference, Susan H. Connors, President and CEO of the Brain Injury Association of America (BIAA), endorsed the National Brain Injury S...Full story

Wednesday, March 12, 2014

FDA Approval For Qudexy XR (Topiramate) Extended-Release Cap...

From NeurologyWire

Upsher-Smith Laboratories, Inc. received approval on March 11, 2014 from FDA for Qudexy XR (topiramate) extended-release capsules, a once-daily, broad...Full story

FDA allows marketing of first medical device to prevent migr...

From NeurologyWire

FDA has allowed marketing of the first device as a preventative treatment for migraine headaches. This is also the first transcutaneous electrical ner...Full story